Viscosupplement — Intra-articular Injection Pregnancy: Limited data — avoid unless clearly necessary; minimal systemic absorption expected

Hyaluronic Acid (Viscosupplementation)

Brand names: Durolane, Ostenil, Synvisc

Adult dose

Dose: Single 3 mL injection (Durolane — single injection); or weekly 2 mL injections × 3–5 (Ostenil — multi-injection protocols)

Route: Intra-articular injection

Frequency: Single injection (Durolane) or weekly × 3–5 (Ostenil/Synvisc)

Max: Repeat courses every 6–12 months

For symptomatic knee osteoarthritis. Exclude infection before injection. Use sterile technique — septic arthritis risk. Ultrasound guidance improves accuracy. Avoid strenuous activity for 48 hours post-injection.

Paediatric dose

Route:

Not routinely used in paediatric patients — seek specialist opinion

Dose adjustments

Renal

No systemic absorption — no dose adjustment required

Hepatic

No dose adjustment required

Clinical pearls

NICE NG226 (Osteoarthritis 2022): NICE does NOT recommend hyaluronic acid injections for osteoarthritis — insufficient clinical benefit over placebo; many injections of joint fluid have placebo effects from the injection procedure itself
Despite NICE guidance, viscosupplementation remains widely used in private practice and NHS in some centres — significant controversy regarding efficacy; meta-analyses show small to moderate benefit over placebo
Larger cross-linked hyaluronic acid polymers (Durolane) have longer residence time in joint (~4–6 weeks) versus smaller HA (Ostenil — excreted faster); clinical significance of this difference is debated
Most useful in mild-moderate knee OA (KL grade 2–3) — evidence weakest in severe OA (grade 4); joint replacement may be more appropriate in severe disease
Drain effusion before injection: injecting viscosupplement into a joint with large effusion dilutes the preparation and may reduce efficacy; aspirate first

Contraindications

Suspected septic arthritis or joint infection
Hypersensitivity to hyaluronic acid or bird proteins (avian-derived preparations)
Skin disease at injection site
Effusion before injection — drain joint before injecting

Side effects

Post-injection flare — pain and swelling 24–72 hours after injection (occurs in 5–10%); more common with multi-injection protocols
Local injection site reactions
Septic arthritis — rare but serious (~1:50,000)
Hypersensitivity reactions (avian-derived preparations)

Interactions

No significant systemic drug interactions

Monitoring

Post-injection flare assessment at 48–72 hours
Signs of septic arthritis — fever, acute worsening, systemic signs
Clinical response at 8–12 weeks

Reference: BNFc; BNF 90; NICE NG226 (Osteoarthritis 2022); Cochrane Review (Viscosupplementation 2022); EULAR Knee OA Recommendations; SPC Durolane. Verify against your local formulary and the latest BNF before prescribing.

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways